for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Enanta Pharmaceuticals Inc

ENTA.OQ

Latest Trade

63.51USD

Change

1.66(+2.68%)

Volume

69,572

Today's Range

61.49

 - 

63.72

52 Week Range

57.26

 - 

106.23

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
61.85
Open
61.96
Volume
69,572
3M AVG Volume
4.09
Today's High
63.72
Today's Low
61.49
52 Week High
106.23
52 Week Low
57.26
Shares Out (MIL)
19.68
Market Cap (MIL)
1,217.31
Forward P/E
26.43
Dividend (Yield %)
--

Next Event

Q4 2019 Enanta Pharmaceuticals Inc Earnings Release

Latest Developments

More

New Data From Enanta’s Phase 2A Human Challenge Study Of EDP-938 For RSV Demonstrates Highly Statistically Significant Reductions (P<0.001) In Total Symptom Score, Mucus Weight And RSV Viral Loa

Enanta Pharmaceuticals Announces Positive Results Of Argon-1 Study Of Its Lead FXR Agonist, Edp-305

Enanta Pharma Posts Q3 Earnings Per Share Of $0.33

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV). It has discovered novel protease inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). These protease inhibitors, developed through its collaboration with AbbVie Inc. (AbbVie), include paritaprevir and glecaprevir (ABT-493). Its product candidates also include EDP-305, which is a farnesoid X receptor (FXR) agonist product candidate for NASH and PBC, and EDP-938, which is a clinical candidate for RSV.

Industry

Biotechnology & Drugs

Contact Info

500 Arsenal St

+1.617.6070800

https://www.enanta.com/

Executive Leadership

Bruce L A Carter

Independent Chairman of the Board

Jay R. Luly

President, Chief Executive Officer, Director

Paul J. Mellett

Chief Financial Officer, Senior Vice President - Finance & Administration

Yat Sun Or

Senior Vice President - Research & Development, Chief Scientific Officer

Nathaniel S. Gardiner

Senior Vice President, General Counsel

Key Stats

2.50 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.2K

2019(E)

0.2K
EPS (USD)

2016

1.130

2017

0.910

2018

3.480

2019(E)

2.319
Price To Earnings (TTM)
20.07
Price To Sales (TTM)
5.51
Price To Book (MRQ)
2.72
Price To Cash Flow (TTM)
18.00
Total Debt To Equity (MRQ)
0.41
LT Debt To Equity (MRQ)
0.41
Return on Investment (TTM)
15.80
Return on Equity (TTM)
15.16

Latest News

Latest News

Enanta Pharma's NASH drug meets mid-stage study goal

Enanta Pharmaceuticals Inc said on Wednesday its drug to treat non-alcoholic steatohepatitis (NASH) met the main goal of reducing levels of elevated liver enzymes in a mid-stage study.

Enanta's lung infection therapy succeeds in mid-stage trial

Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study.

REFILE-Enanta's lung infection therapy succeeds in mid-stage trial

Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body and improving symptoms in patients in a mid-stage study.

BRIEF-Enanta Pharmaceuticals Reports Q2 Earnings Per Share $0.61

* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL SECOND QUARTER ENDED MARCH 31, 2018

BRIEF-Enanta Pharmaceuticals Reports Q1 Earnings Per Share $0.59

* ENANTA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR ITS FISCAL FIRST QUARTER ENDED DECEMBER 31, 2017

BRIEF-Enanta Pharmaceuticals Says Phase 1 Clinical Study Of Edp-938 For Respiratory Syncytial Virus Initiated

* ENANTA PHARMACEUTICALS TO PROVIDE UPDATES ON ITS RESEARCH AND DEVELOPMENT PROGRAMS AND BUSINESS OUTLOOK FOR 2018 DURING THE 36TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

BRIEF-Enanta Pharma Says Abbvie’s Maviret ‍is Now Commercially Available In Japan​

* ENANTA PHARMACEUTICALS - ABBVIE'S MAVIRET HAS BEEN APPROVED FOR REIMBURSEMENT BY MINISTRY OF HEALTH, LABOUR AND WELFARE

BRIEF-Enanta Pharma Q4 earnings per share $1.86

* Enanta Pharmaceuticals reports financial results for its fourth quarter and year ended september 30, 2017

BRIEF-Enanta Pharmaceuticals reports positive phase 1 A/B clinical results for its lead fxr agonist

* Enanta Pharmaceuticals announces positive phase 1 a/b clinical results for its lead fxr agonist, edp-305

BRIEF-Enanta Pharmaceuticals announces new data presentations on EDP-305

* Enanta Pharmaceuticals announces new data presentations on EDP-305, an FXR agonist for NASH and PBC, at The Liver Meeting 2017

BRIEF-Enanta says Abbvie’s Maviret approved in Japan for the treatment of all major genotypes of chronic hepatitis c

* Enanta announces that Abbvie’s Maviret (glecaprevir/pibrentasvir) received approval in Japan for the treatment of all major genotypes (GT1-6) of chronic hepatitis c

BRIEF-Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

* Enanta Pharmaceuticals announces the appointment of Kristine Peterson to its board of directors

BRIEF-Enanta pharmaceuticals Q3 loss per share $0.44

* Enanta pharmaceuticals reports financial results for its fiscal third quarter ended june 30, 2017

BRIEF-Enanta Pharmaceuticals announces new data on EDP-938

* Phase 1 clinical study for RSV expected to begin in fourth calendar quarter of 2017

BRIEF-Enanta announces that AbbVie receives CHMP positive opinion for MAVIRET

* Enanta announces that abbvie receives chmp positive opinion for maviret™ (glecaprevir/pibrentasvir) for the treatment of chronic hepatitis c in all major genotypes (gt1-6)

BRIEF-Enanta Pharmaceuticals reports Q2 loss per share $0.28

* Enanta Pharmaceuticals reports financial results for its fiscal second quarter ended March 31, 2017

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

BRIEF-Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B

* Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c

BRIEF-Enanta Pharmaceuticals Q1 loss per share $0.26

* Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended december 31, 2016

BRIEF-Enanta pharmaceuticals says EMA grants accelerated assessment for Abbvie's investigational HCV regimen of Glecaprevir/Pibrentasvir

* Says EMA grants accelerated assessment for Abbvie's investigational HCV Regimen Of Glecaprevir/Pibrentasvir

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up